![]() Mesothelioma also responded, perhaps because the asbestos that caused it also inflames the immune system. It is caused by a virus, and researchers suggested the infection itself draws the attention of the immune system. An unusual skin cancer called Merkel cell carcinoma responded to immunotherapy, scientists found. "For the vast majority of cancers, there is an amazingly clean correlation between response to therapy and mean mutational load," Pardoll said. The article says immunotherapy doesn't work on all cancers, in fact only a few to date - though expanded testing on all forms of cancer may begin soon. Anyway, a drug to keep an eye on to see if the other 5 patients do well, or don't do well, so that if you read of someone taking Yescarta in the future you'll have some reasonable expectations as to what that means.Ī bit of a fluff piece, but here's an article about someone who used ' immunotherapy' (nivolumab) to cure ovarian cancer. Pretty safe to say the drug had zero or nearly so effect. However, when put into practice of our small sample size of 6, we already have 1 person (16%) who didn't last 50 days. So what have we? Unsure of what cancers the trial patients had, but a bit less than half taking the drug achieved some beneficial results, with some extraordinary results as well. ![]() McCulley received her reprogrammed T cells just before Christmas 2017. She had been one of the first 6 people in the country to try Yescarta (allowed/perscribed only after chemotherapy and radiation have been unsuccessful). She died Februafter a yearlong battle with lymphoma. Īnd my Yescarta research was instigated by the death of Kristine McCulley (58). Yescarta was only approved by the FDA in October 2017, and despite some early promoted as a breakthrough by maker Gilead Sciences, Inc., only 6 patients have actually gotten the costly therapy, while others linger on waiting lists. ![]() In this analysis, 12% of patients experienced grade 3 or higher cytokine release syndrome (CRS), and 31% experienced neurologic toxicities." Indeed, 42% of patients continue to respond to Yescarta, and 40% are disease-free. " After a (median) 1 5.4 month follow-up, shows that more than half of patients are still progression-free. Returned to the patient, the revved-up cells can continue multiplying to fight the disease for months or even years. Yescarta, also referred to as a CAR-T therapy, works like this: T cells, or immune system cells, are filtered from a patient’s blood and reprogrammed to target and kill cancer cells. Am I going to tell you who had a Whipple procedure done and when? Of course not.Īnyway, what instigated this was I needed a place to post about this new refractory large B-cell lymphoma gene therapy treatment called Yescarta. Isn't that something we all should know? Of course. You see someone getting a Whipple procedure, pencil them in for your DPs 12-18 months down the road, depending on age I reckon. It's not like we are sharing NAMES of people with said afflictions.įor instance, my research shows a person undergoing the Whipple procedure for pancreatic cancer adds about 18 months to their lives. I am aware of and understand the competitive nature that brews in these parts-I mean I want to win a DP as much as anyone-but if we collectively can spot trends in medicine, seems a reasonable thing to share. You see something that says 20% of all patients undergoing a medical procedure recover fully, I (well we) need to know and act accordingly when putting together out DP lists. I want a place we can post information/data about diseases or medical conditions, their various treatments, and potential recoveries (%age) or life expectancies therefrom.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |